Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 1999

View Archived Issues

New small-molecule HIV protease inhibitors reported

EntreMed extends angiogenesis research agreement with Children's Hospital of Boston

Phase II ranolazine data published in The American Journal of Cardiology

FDA approves initiation of Progen's phase I trial in Australia for PI-88

ZymeTx returns anti-HIV compound to Oklahoma Medical Research Foundation

Unimed seeks approval for Androgel in the U.S.

Allotrap-1258, a rationally designed immunomodulating peptide for the prevention of GvHD

Cell Genesys completes phase I/II GVAX trial and earns milestone payment

New company formed to accelerate R&D of orphan nuclear receptors

Nesiritide is safe and effective in patients with symptomatic decompensated CHF

Taiho obtains exclusive worldwide rights to potential breast cancer treatment

Demegen peptides active against multidrug-resistant bacteria

Chiron develops novel gene therapy for degenerative retinal disorders

Selective Genetics' GAM technology enhances delivery and retention of NTF gene therapy

Phenylcarboxylates for lipid disorders synthesized and tested at Taiho

New AMPA receptor antagonists designed at Kyorin

Search for therapeutically effective protein farnesyltransferase inhibitors continues at Merck

Novel glycoside antithrombotic agents in the pipeline at Gedeon Richter

Expectorants developed at Sawai more effective than ambroxol in animal model

LG Chemical presents wide series of imidazoles useful as inhibitors of protein farnesyltransferase

Mechanism of action of new centrally acting muscle relaxant silperisone examined

Anorexigenic cytokine gene therapy: a new approach to treating obesity

Recent advances in gene therapy of cystic fibrosis

CGP-3466B proves effective as neuropotectant both in vitro and in vivo

Sanofi-Synthelabo's SR-58611 normalizes wound healing in diabetic and obese mice

Animal studies with KC-12792 point to potential of NEP inhibitors in management of heart failure

Potent, selective and orally bioavailable p38 MAP kinase inhibitor selected as development candidate

Phase II testing of promising cardiovascular drug well under way at Merck

New cardiovascular disease candidate from Merck KGaA enters phase II